Arrakis Therapeutics, a biopharmaceutical company engaged in the discovery of a new class of small molecule medicines that directly target RNA, has entered a collaboration and license agreement with Roche for the discovery of RNA-targeted small molecule (rSM) drugs against a broad set of targets across all of Roche’s research and development areas.   Arrakis will lead discovery and research activities for each target to a defined point, at which time Roche will have the right to exclusively purs...